Literature DB >> 30343112

Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc.

Jingyi Zhang1, Pengwei Ren2, Da Xu1, Xiaofeng Liu1, Zhenzhen Liu1, Chunfeng Zhang3, Yuan Li1, Lijun Wang1, Xiaojuan Du4, Baocai Xing5.   

Abstract

Nucleolar protein hUTP14a is required for 18S rRNA processing and promotes p53 degradation. Here, we report that hUTP14a stabilizes c-Myc in colorectal cancer (CRC) progression. Firstly, nucleolar hUTP14a is upregulated in human CRC tissues. Mass spectrometry analysis identified c-Myc and its deubiquitinase ubiquitin-specific protease 36 (USP36) in the hUTP14a-specific complex. Importantly, hUTP14a interacts with c-Myc and protects c-Myc from ubiquitination and degradation in a USP36-dependent way. We further demonstrate that hUTP14a forms a complex with USP36/Fbw7γ to inhibit Fbw7γ-mediated c-Myc degradation. Ectopic expression of Flag-hUTP14a enriches c-Myc in the nucleolus, indicating hUTP14a stabilizes c-Myc in the nucleolus. Interestingly, c-Myc activates transcription of hUTP14a. Knockdown of hUTP14a by short hairpin RNA inhibits tumor growth and decreases c-Myc levels in mouse xenografts. Significantly, nucleolar hUTP14a and c-Myc are co-upregulated in human CRC tissues, and this co-upregulation indicates poor prognosis of CRC patients. Thus, disruption of hUTP14a-c-Myc regulation may provide a potential therapeutic strategy for a subset of CRC patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Protein degradation; c-Myc; hUTP14a

Mesh:

Substances:

Year:  2018        PMID: 30343112     DOI: 10.1016/j.canlet.2018.10.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  [Expression of hUTP14a in non-small cell lung cancer].

Authors:  C F Zhang; Y Liu; M Lu; X J DU
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-02-18

2.  CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1.

Authors:  Han Ling; Chen-Hui Cao; Kai Han; Yong-Rui Lv; Xiao-Dan Ma; Jing-Hua Cao; Jie-Wei Chen; Si Li; Jin-Long Lin; Yu-Jing Fang; Zhi-Zhong Pan; Dan Xie; Feng-Wei Wang
Journal:  Oncogene       Date:  2022-08-22       Impact factor: 8.756

Review 3.  Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy.

Authors:  Liangliang Xing; Leidi Xu; Yong Zhang; Yinggang Che; Min Wang; Yongxiang Shao; Dan Qiu; Honglian Yu; Feng Zhao; Jian Zhang
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 4.  Basic approaches, challenges and opportunities for the discovery of small molecule anti-tumor drugs.

Authors:  Yu-Shui Ma; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Yi Shi; Dan-Dan Zhang; Hui-Min Wang; Pei-Yao Wang; Qin-Lu Lin; Wen Li; Da Fu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 5.  How Cancer Exploits Ribosomal RNA Biogenesis: A Journey beyond the Boundaries of rRNA Transcription.

Authors:  Marco Gaviraghi; Claudia Vivori; Giovanni Tonon
Journal:  Cells       Date:  2019-09-17       Impact factor: 6.600

Review 6.  Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment.

Authors:  Xiuzhen Zhang; Tong Meng; Shuaishuai Cui; Ling Feng; Dongwu Liu; Qiuxiang Pang; Ping Wang
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

7.  Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway.

Authors:  Xiaofeng Liu; Kunqi Su; Xiaoyan Sun; Yang Jiang; Lijun Wang; Chenyu Hu; Chunfeng Zhang; Min Lu; Xiaojuan Du; Baocai Xing
Journal:  J Exp Clin Cancer Res       Date:  2021-04-15

8.  Overexpression of U three protein 14a (UTP14a) is associated with poor prognosis of esophageal squamous cell carcinoma.

Authors:  Kun-Kun Li; Cheng-Yi Mao; Jing-Ge Zhang; Qiang Ma; Ying-Jian Wang; Xue-Hai Liu; Tao Bao; Wei Guo
Journal:  Thorac Cancer       Date:  2019-09-08       Impact factor: 3.500

9.  Targeting Colorectal Cancer Stem Cells as an Effective Treatment for Colorectal Cancer.

Authors:  Yu-Shui Ma; Wen Li; Yu Liu; Yi Shi; Qin-Lu Lin; Da Fu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 10.  Ribosome Biogenesis Alterations in Colorectal Cancer.

Authors:  Sophie Nait Slimane; Virginie Marcel; Tanguy Fenouil; Frédéric Catez; Jean-Christophe Saurin; Philippe Bouvet; Jean-Jacques Diaz; Hichem C Mertani
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.